Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: cancer drug + cancer + commentary  Related to the article below (Last Update: 5/12/2008)

Risk of death, strokes higher when patients given beta blockers ...
The Canadian Press, TORONTO -
The findings suggest that for every 1000 patients who get the drug, 15 non-fatal heart attacks would be prevented, three angioplasty or bypass surgeries ...
Benefits In Chronic Pain Outweigh Risks For Painkiller Abuse
Medical News Today (press release), UK -
"Now I hope history repeats itself in changing professional and public attitudes as we now know opioids are effective for treating chronic non-cancer pain ...
A Miracle Drug That Reduces Cancer, Other Chronic Diseases
Evening Bulletin, PA - Apr 30, 2008
Here comes an incredibly powerful drug that will cut your risk of a heart attack by 15-51 percent and also reduce your risk of cancer, diabetes and many ...

Healthcare Today
Cancer's stem cell connection
Healthcare Today, UK - May 6, 2008
Treatments for cancer will be influenced by the discovery that stem cells are thought to cause the growth of tumours, says an article in The Economist. ...
pSivida Quarterly Cash Flow ? March 31, 2008 Commentary and Highlights
Business Wire (press release), CA - Apr 30, 2008
Pancreatic cancer is the 4th highest cause of death by cancer in the US. Median survival for people with inoperable primary pancreatic cancer or metastatic ...PSDV - WAR:CFL
Commentary: More drug questions, more worries about doctoring ...
Oshkosh Northwestern, WI - Apr 16, 2008
For example, it is known that both smoking and asbestos exposure cause lung cancer. If you combine smoking and exposure to asbestos in the same person the ...
Stocks, commodities end flat on mixed news
Vancouver Sun,  Canada - Apr 18, 2008
Tests on lab mice showed the company's lead cancer drug was effective in treating both breast cancer and colon cancer. In the breast cancer testing, ...
Your letters: Marijuana
Ventura County Star, CA - May 5, 2008
If a doctor recommends marijuana to cancer patients undergoing chemotherapy and it helps them feel better, then it's working. In the end, medical marijuana ...
Unsung Heroines: Eight local women honored for fighting for their ...
Eagle Tribune, MA - May 11, 2008
The oldest of six children, she faced many challenges, including her mother's struggle with cancer and her ultimate death at age 47. ...
States Crack Down On Online Gene Tests
Forbes, NY - Apr 18, 2008
For example, 23andMe tests for some gene variants involved in mildly raising breast cancer risk, but not genes called BRCA1 and BRCA2 that vastly raise ...DNA - GOOG
Source: Google News

… and Bioinformatics Approaches for Identification of Serum Biomarkers to Detect Breast Cancer -
J Li, Z Zhang, J Rosenzweig, YY Wang, DW Chan - Clinical Chemistry, 2002 - Am Assoc Clin Chem
... Proteomics and Bioinformatics Approaches for Identification of Serum Biomarkers
to Detect Breast Cancer. ... Home page, Cancer Epidemiol. Biomarkers Prev. ...

… Drug Dose as Risk Factors for Late Cardiotoxic Effects of Doxorubicin Therapy for Childhood Cancer -
SE Lipshultz, SR Lipsitz, SM Mone, AM Goorin, SE … - New England Journal of Medicine, 1995 - content.nejm.org
... Next Next. Female Sex and Higher Drug Dose as Risk Factors for Late Cardiotoxic
Effects of Doxorubicin Therapy for Childhood Cancer. ...

Risk of cancer after use of fertility drugs with in-vitro fertilisation -
A Venn, L Watson, F Bruinsma, G Giles, D Healy - Lancet, 1999 - Mass Med Soc
Summaries and commentary of medical ... In previous smaller studies, standard fertility
drug dosages were ... with increases in breast or endometrial cancer, and the ...

Phase I Clinical Trial Design in Cancer Drug Development -
EA Eisenhauer, PJ O?Dwyer, M Christian, JS … - Journal of Clinical Oncology, 2000 - jco.ascopubs.org
... COMMENTARY AND DISCUSSION. ... of toxicity/efficacy relationship seen with traditional
cytotoxic anticancer drugs. ... agents in volunteers, but if cancer patients are ...

From the Cover: Prospective identification of tumorigenic breast cancer cells -
M Al-Hajj, MS Wicha, A Benito-Hernandez, SJ … - Proceedings of the National Academy of Sciences, 2003 - National Acad Sciences
... cancer drug resistance protein, and multiple drug resistance (29 ... Flow cytometry was
supported by National Cancer Institute Grant CA ... See commentary on page 3547. ...

… Shock Protein 90-binding Drugs: A Ligand-independent Approach to Hormonal Therapy of Breast Cancer -
R Bagatell, O Khan, G Paine-Murrieta, CW Taylor, S … - Clinical Cancer Research, 2001 - AACR
... Pearl, and C. Prodromou Sensitivity to Hsp90-targeting drugs can arise ... Therapeutic
Approach for Treating Hormone-refractory Prostate Cancer : Commentary re: DB ...

Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy -
N Immunology, D Discovery - Nature Medicine, 2001 - palgrave-journals.com
Commentary. ... Anti-angiogenic scheduling of chemotherapy improves efficacy against
experimental drug?resistant cancer. Cancer Res. 60, 1878?1886 (2000). ...

Pharmacologic Treatment of Cancer Pain -
MH Levy - New England Journal of Medicine, 1996 - content.nejm.org
... Patients With Cancer. JAMA 279: 1877-1882 [Abstract] [Full Text]; White, S., Wong,
SHY (1998). Standards of laboratory practice: analgesic drug monitoring. ...

Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment: Challenges for Drug … -
KA Gelmon, EA Eisenhauer, AL Harris, MJ Ratain, P … - jnci, 1999 - jnci.oxfordjournals.org
... Organization for Research and Treatment of Cancer Symposium on New Drugs in Cancer
Therapy, a workshop discussed these issues. In this commentary, we summarize ...

… and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a … -
T Le Chevalier, D Brisgand, JY Douillard, JL Pujol … - Journal of Clinical Oncology, 1994 - jco.ascopubs.org
... and JP Pignon Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy
Regimen in Advanced Non-Small-Cell Lung Cancer: A Meta-analysis JAMA, July ...

Source: Google Scholar

Impact Of Taking Cancer Drug With Food Highlighted By Commentary
A commentary in the Journal of Clinical Oncology (JCO) urges researchers to explore an intriguing approach to reduce the dose, and therefore the cost, of oral targeted cancer therapies. The commentary, by Mark Ratain, MD and Ezra Cohen, MD of the University of Chicago, examines recent pharmacologic research which found that taking the targeted therapy lapatinib (Tykerb) with food significantly increased the concentration of the drug in the body. The commentary suggests that taking lapatinib with food instead of on an empty stomach, as currently indicated, could cut the needed dose by at least 60 percent, reducing the cost accordingly. The authors stress that formal studies are needed to determine the effectiveness of this approach. The article is published in the Journal of Clinical Oncology.
The commentary focuses on a study presented at the March 2007 meeting of the American Society for Clinical Pharmacology and Therapeutics, which found that lapatinib is more readily absorbed by the body when taken with food, particularly a high-fat meal. As a result, 500 mg of lapatinib taken with food may be as effective as taking the currently approved 1,250 mg without food.

Lapatinib was approved by the U.S. Food and Drug Administration (FDA) in March of this year for women with advanced HER2-positive breast cancer. The FDA approved the 1,250 mg dose of lapatinib based on a large phase III clinical trial demonstrating its effectiveness and safety at that dose without food. It is taken as five 250 mg tablets on an empty stomach and costs $2,900 per month.

The cost of new targeted cancer therapies -- which can be as high as $10,000 per month -- has generated substantial discussion and debate. "The economic implications of this food effect study are particularly remarkable. At the current price of $2,900 per month, this would have a cost savings of 60 percent or $1,740 per month" the commentary states. "As we enter an era of 'targeted' anticancer agents with a monthly cost measured in the thousands of dollars, we should view drug-drug or drug-food interactions as opportunities to lower costs."

The commentary states that rising cancer drug prices are encouraging researchers to explore such pharmacologic approaches to lowering costs. However, the authors urge that neither physicians nor patients consider changing lapatinib dose based on these findings, and that everyone strictly follow the prescribing label directions, which are based on the findings of rigorous clinical tests. The authors strongly emphasize that a formal pharmacokinetic study of a lower dose of lapatinib with food would need to confirm these findings before any change in dosage could be considered safe and effective.

"The Value Meal: How to Save $1,700 Per Month or More on Lapatinib." Mark J. Ratain, MD and Ezra E. Cohen, MD, University of Chicago, Chicago, IL.
The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians of all oncology subspecialties who care for people with cancer. ASCO's nearly 25,000 members from the United States and abroad set the standard for patient care and lead the efforts to discover more effective cancer treatments, increase funding for clinical and translational research, and, ultimately, improve cancer care for the estimated 10 million people diagnosed with cancer worldwide each year. ASCO publishes the Journal of Clinical Oncology (JCO), the preeminent, peer-reviewed, medical journal on clinical cancer research, and produces People Living With Cancer (http://www.plwc.org/), a comprehensive consumer website providing oncologist-vetted cancer information to help patients and families make informed health-care decisions.

Source: Tiffany Reynolds
American Society of Clinical Oncology
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
ALL THE NEWS : News1 ; News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.